Stem-cell hemotoxicity testing firm HemoGenix this week announced the launch of a 384-well plate version of its flagship HALO bioluminescent assay system for determining the effects of drugs on hematopoietic stem cells.

HemoGenix, which has traditionally garnered the majority of its revenues from contract hemotoxicity testing, hopes that the new higher throughput format will spur direct sales of its assay kits to pharmaceutical companies wishing to perform such testing in house, HemoGenix CEO Ivan Rich said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.